Discontinued Productp-DITC-APEC (Cat. No. 2405) has been withdrawn from sale for commercial reasons.
Irreversible A2A receptor agonist (apparent Ki = 9.9 nM). Displays > 8-fold selectivity for A2 versus A1 receptors (Ki values are 35 and 276 nM for rat A2 and A1 receptors respectively). Produces progressive concentration-independent vasodilation in guinea pig heart Langendorff preparations.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Jacobson et al (1992) Chemical modification and irreversible inhibition of striatal A2A adenosine receptors. Mol.Pharmacol. 42 123 PMID: 1635550
Jacobson et al (1989) Agonist derived molecular probes for A2 adenosine receptors. J.Mol.Recog. 2 170
Niiya et al (1993) Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn-Schmied.Arch.Pharmacol. 347 521
View Related Products by Product Action
Keywords: p-DITC-APEC, p-DITC-APEC supplier, A2A, adenosines, agonist, Adenosine, Receptors, 2405, Tocris Bioscience
Citations for p-DITC-APEC
Citations are publications that use Tocris products.
Currently there are no citations for p-DITC-APEC.
Reviews for p-DITC-APEC
There are currently no reviews for this product. Be the first to review p-DITC-APEC and earn rewards!
Have you used p-DITC-APEC?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.